Jason D. Mitchell

Array ( [id] => 19770034 [patent_doc_number] => 20250051460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES [patent_app_type] => utility [patent_app_number] => 18/808311 [patent_app_country] => US [patent_app_date] => 2024-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18808311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448976 [patent_doc_number] => 20240309106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => IMMUNE CELLS HAVING CO-EXPRESSED SHRNAS AND LOGIC GATE SYSTEMS [patent_app_type] => utility [patent_app_number] => 18/677547 [patent_app_country] => US [patent_app_date] => 2024-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18677547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556485 [patent_doc_number] => 20240368277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/625774 [patent_app_country] => US [patent_app_date] => 2024-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658529 [patent_doc_number] => 20240425594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => NOVEL PD-1 BINDING DOMAINS [patent_app_type] => utility [patent_app_number] => 18/625703 [patent_app_country] => US [patent_app_date] => 2024-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658530 [patent_doc_number] => 20240425595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => NOVEL PD-1 BINDING DOMAINS [patent_app_type] => utility [patent_app_number] => 18/625756 [patent_app_country] => US [patent_app_date] => 2024-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402287 [patent_doc_number] => 12492256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Methods and compositions for modulating beta chain mediated immunity [patent_app_type] => utility [patent_app_number] => 18/609023 [patent_app_country] => US [patent_app_date] => 2024-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 43 [patent_no_of_words] => 147518 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18609023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800545 [patent_doc_number] => 20250066470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => TIGIT AND CD112R BLOCKADE [patent_app_type] => utility [patent_app_number] => 18/435746 [patent_app_country] => US [patent_app_date] => 2024-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18435746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497683 [patent_doc_number] => 20240336701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES [patent_app_type] => utility [patent_app_number] => 18/427264 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622669 [patent_doc_number] => 12590168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof [patent_app_type] => utility [patent_app_number] => 18/420588 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 10 [patent_no_of_words] => 43660 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032542 [patent_doc_number] => 20240082357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISCHEMIA AND CARDIOMYOPATHY [patent_app_type] => utility [patent_app_number] => 18/517957 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217884 [patent_doc_number] => 20240182588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => Anti-CCR8 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/512759 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172510 [patent_doc_number] => 20240158484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/487900 [patent_app_country] => US [patent_app_date] => 2023-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18487900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227211 [patent_doc_number] => 12415854 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Antibodies to TIGIT [patent_app_type] => utility [patent_app_number] => 18/486086 [patent_app_country] => US [patent_app_date] => 2023-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 29 [patent_no_of_words] => 32722 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19052229 [patent_doc_number] => 20240094198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES [patent_app_type] => utility [patent_app_number] => 18/369273 [patent_app_country] => US [patent_app_date] => 2023-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18369273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521120 [patent_doc_number] => 12122828 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => IL-7 binding proteins and their use in medical therapy [patent_app_type] => utility [patent_app_number] => 18/460944 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 27 [patent_no_of_words] => 48250 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112823 [patent_doc_number] => 20240124573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR) [patent_app_type] => utility [patent_app_number] => 18/447623 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939676 [patent_doc_number] => 20240034815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3 [patent_app_type] => utility [patent_app_number] => 18/358884 [patent_app_country] => US [patent_app_date] => 2023-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18358884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902739 [patent_doc_number] => 20240018224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ANTI-GPC3 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/335477 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311604 [patent_doc_number] => 12037407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Immune cells having co-expressed shRNAS and logic gate systems [patent_app_type] => utility [patent_app_number] => 18/311856 [patent_app_country] => US [patent_app_date] => 2023-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 110 [patent_no_of_words] => 86072 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18598411 [patent_doc_number] => 20230273210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => SYSTEMS AND METHODS FOR PREDICTING GRAFT DYSFUNCTION WITH EXOSOME PROTEINS [patent_app_type] => utility [patent_app_number] => 18/180991 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18180991 [rel_patent_id] =>[rel_patent_doc_number] =>)